Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review
Rheumatology International · 18.07.2026 · 46 (8)
DOI: 10.1007/s00296-026-06256-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Rheumatology International, online erschienen am 18.07.2026. Verfasst von Wiktoria Niebudek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland. wiktoria.j.niebudek@gmail.com. Hauptthemen laut MEDLINE: Fasciitis, Eosinophilia, Antibodies, Monoclonal, Humanized, Biological Products. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
Eosinophilic fasciitis (EF) is a rare autoimmune disease characterized by fascial inflammation, skin induration, eosinophilia, and progressive functional impairment. Although glucocorticosteroids (GCs) remain the first-line therapy, some patients develop refractory or steroid-dependent disease, highlighting the need for alternative treatment strategies. This case-based review summarizes current evidence on biologic and targeted therapies in severe EF and presents a case of successful treatment with tocilizumab (TCZ). A systematic review of PubMed, Scopus, and Web of Science databases identified 35 eligible articles published between 2008 and 2026. Qualitative synthesis included 49 patients treated with biologic or targeted agents, most commonly rituximab (n = 14), tocilizumab (n = 9), infliximab (n = 7), and mepolizumab (n = 5). Partial or complete response was achieved in 47 of 49 (96%) patients across all treatment groups. Biologic therapy was associated with a pronounced steroid-sparing effect, enabling GCs dose reduction or complete withdrawal in the majority of refractory patients. Furthermore, we describe a 28-year-old man with progressive, treatment-resistant EF who failed to respond adequately to GCs and methotrexate. Following initiation of weekly subcutaneous TCZ, the patient showed marked clinical, laboratory, and radiological improvement, with normalization of inflammatory markers, regression of fascial edema on MRI, and substantial functional recovery. Available case-based evidence suggests that biologic and targeted therapies, including IL-6 inhibition, may be promising options in selected patients with severe, refractory, or GC-dependent EF. However, considering the high risk of publication bias and reliance on case reports, prospective multicenter studies are required to establish standardized treatment recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Cardinal Stefan Wyszyński University in Warsaw, Warsaw, Poland. wiktoria.j.niebudek@gmail.com.
- Rheumatology Student Research Group, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland. wiktoria.j.niebudek@gmail.com.
- Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland.
- ''Rheumaticus'' Student Research Group at the Medical University of Warsaw, Warsaw, Poland.
- Department of Connective Tissue Disease, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
- Department of Rheumatology, Eleonora Reicher National Institute of Geriatrics, Rheumatology and Rehabilitation, Spartańska 1, 02-637, Warsaw, Poland.
Zitieren
APA
Niebudek, W., Krupa, M., Dziewit, M., Olesińska, M., & Maślińska, M. (2026). Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review. Rheumatology International, 46(8). https://doi.org/10.1007/s00296-026-06256-4
Vancouver
Niebudek W, Krupa M, Dziewit M, Olesińska M, Maślińska M. Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review. Rheumatology International. 2026;46(8). doi:10.1007/s00296-026-06256-4
BibTeX
@article{Niebudek2026,
author = {Niebudek, Wiktoria and Krupa, Michał and Dziewit, Martyna and Olesińska, Marzena and Maślińska, Maria},
title = {Favorable clinical outcomes of biologic and targeted therapies in refractory eosinophilic fasciitis: a case-based systematic review},
journal = {Rheumatology International},
year = {2026},
volume = {46},
number = {8},
doi = {10.1007/s00296-026-06256-4}
}
EUVIMED